This document serves as a formal correction to a 2018 study published in Oncotarget. While the core findings of the original research remain intact, this update addresses a critical typographical error in the reporting of drug potency—a correction vital for researchers replicating these findings or using them as a baseline for clinical dosage calculations.
Abstract
This correction fixes a unit-of-measurement error in the potency data ($IC_{50}$ values) for CDK4/6 inhibitors, changing "μM" to "nM." The data reaffirms that ribociclib is a highly potent and selective inhibitor, particularly in CDK4-dependent cancer models, showing an 8-fold selectivity over CDK6-dependent lines.
The Importance of Scale in Pharmacology
In pharmacological research, scale is paramount. The original 2018 paper explored the versatility of the CDK4/6 inhibitor ribociclib (LEE011) across various preclinical cancer models but inadvertently reported its half-maximal inhibitory concentration ($IC_{50}$) in micromolar (μM) units.
The corrected data clarifies that the values are actually in nanomolar (nM) units, representing a 1,000-fold difference in potency. For the scientific community, this distinction differentiates a moderately active compound from one that is highly potent and clinically viable. This correction ensures the scientific record accurately reflects the high sensitivity of various cancer cell lines, including breast cancer and leukemia, to these inhibitors.
Experimental Approach
Researchers utilized the CyQuant cell proliferation assay to determine $IC_{50}$ values. This standard fluorescence-based method measures cell density by quantifying DNA content. By treating a panel of eight human cancer cell lines with increasing concentrations of three inhibitors—Ribociclib, Palbociclib, and Abemaciclib—the team calculated the precise concentration required to inhibit cell growth by 50%.
Cell Line Classification
The study evaluated the inhibitors across a diverse panel categorized by their "dominant" cyclin-dependent kinase (CDK) dependency:
- CDK4-Dominant Lines: JeKo-1 (Mantle Cell Lymphoma), and CAMA-1, MCF-7, and T47D (ER+ Breast Cancer).
- CDK6-Dominant Lines: REH and SEM (Acute Lymphoblastic Leukemia), Pfeiffer (Diffuse Large B-cell Lymphoma), and MOLM-13 (Acute Myeloid Leukemia).
Key Results and Comparative Potency
The corrected Table 1 provides the specific $IC_{50}$ (mean ± SD, nM) values that define the pharmacological profile of these agents.
Selectivity and Potency Insights
- The Selectivity Gap: A significant finding in this data is the varying selectivity between the three drugs. While all three target both CDK4 and CDK6, they do not do so equally. Ribociclib demonstrates an 8.0-fold average differential in favor of CDK4-dominant lines. In contrast, Palbociclib is nearly non-selective (1.3-fold), and Abemaciclib shows intermediate selectivity (5.5-fold).
- Potency Profiles: Abemaciclib consistently exhibits the lowest $IC_{50}$ values (highest potency) across almost all cell lines, often reaching the low double-digit nanomolar range (e.g., 11 nM in MCF-7). However, ribociclib’s higher selectivity for CDK4 may offer a distinct therapeutic window or side-effect profile in specific clinical contexts.
- Clinical Relevance: The results show that while all three drugs are potent, their profiles diverge significantly when moving from solid tumors (CDK4-dominant) to leukemias (CDK6-dominant). Ribociclib's $IC_{50}$ increases significantly in the ALL (Acute Lymphoblastic Leukemia) lines, highlighting its specific affinity for CDK4.
Conclusion
As this is a correction notice, it focuses on rectifying the data record rather than introducing new experimental findings. The authors emphasize that these corrections do not change the fundamental results or conclusions of the original paper. Ribociclib remains a highly effective and versatile candidate for combination therapies across a wide range of cancer types. Future work continues to focus on identifying biomarkers that predict which patients will benefit most from the high CDK4-selectivity of ribociclib versus the broader potency of abemaciclib.
Summary updated